AstraZeneca announced Monday that Calquence, its oral treatment for blood cancers, showed positive results in a Phase III study.

The drug combined with AbbVie's venetoclax, with or without the antibody obinutuzumab, significantly improved progression-free survival when administered as first-line treatment for chronic lymphocytic leukemia, the company said in a press release.

For the secondary endpoint, a positive trend was observed with the combination of the two compounds, with or without obinutuzumab, compared with the reference treatment of chemotherapy plus immunotherapy, AstraZeneca adds.

The biopharmaceutical group points out, however, that the data were not sufficiently refined to conclude that there were definite results for the secondary endpoint.

Chronic lymphocytic leukemia (CLL) is characterized by a progressive accumulation of malignant B lymphocytes in the blood, bone marrow, spleen and lymph nodes.

Symptoms include fatigue, fevers, night sweats, unintentional weight loss and early satiety.

Copyright (c) 2024 CercleFinance.com. All rights reserved.